Brodalumab

Drug Profile

Brodalumab

Alternative Names: AMG-827; IL-17R mAb; KHK-4827; LUMICEF

Latest Information Update: 13 Dec 2016

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca; Kyowa Hakko Kirin; Valeant Pharmaceuticals International
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 17 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erythrodermic psoriasis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Phase III Spondylarthritis
  • Discontinued Asthma; Crohn's disease; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 02 Dec 2016 Kyowa Hakko Kirin Korea plans a phase III trial for Plaque psoriasis in South Korea (SC) (NCT02982005)
  • 01 Nov 2016 Phase-III clinical trials in Spondylarthritis (Second-line therapy or greater) in Japan (SC) (NCT02985983)
  • 30 Sep 2016 Launched for Erythrodermic psoriasis, Pustular psoriasis, Psoriatic arthritis, Plaque psoriasis in Japan (SC) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top